• Weiss N, et al. Cerebrosprinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy J Hepatol. 2016 Dec;65(6):1120-1130. doi: 10.1016/j.jhep.2016.07.046. Epub 2016 Aug 9. [abstract]
  • Ayman Tourbah, Christine Lebrun-Frenay, Gilles Edan, Michel Clanet, Caroline Papeix, Sandra Vukusic, Jerome De Sèze, Marc Debouverie, Olivier Gout, Pierre Clavelou, Gilles Defer, David-Axel Laplaud, Thibault Moreau, Pierre Labauge, Bruno Brochet, Frédéric Sedel and Jean Pelletier. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Multiple Sclerosis Journal. September 1, 2016. 10.1177 [abstract]
  • Laure Peyro Saint Paula, Danièle Debruyneb, Delphine Bernardc, Donald M. Mockd and Gilles L. Defere Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis. Expert opinion on drug metabolism & toxicology. 2016 February 4.12(3):327-44. [abstract]
  • Frédéric Sedel, Caroline Papeix, Agnès Bellanger, Valérie Touitou, Christine Lebrun-Frenay, Damien Galanaud, Olivier Gout, Olivier Lyon-Caen, Ayman Tourbah. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Multiple Sclerosis and Related Disorders. 2015 Mar;4(2):159-69. [abstract]
  • Sedel F, Bernard D, Mock DM, Tourbarh A. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology. 2015 Sep 5. pii: S0028-3908(15)30073-3. [abstract]

MedDay SA au capital de 116 660 €
Siège social : 96 Boulevard Haussmann 75008 Paris
RCS PARIS 534 957 865
Publication Director : Dr Frédéric Sedel